机构：[1]State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China,[2]Institute of Respiratory Disease, First Hospital of China Medical University, Shenyang, China,[3]Department of Respiratory Disease, Xingqiao Hospital, Third Military Medical University, Chongqing, China,[4]Beijing Novartis Pharma Co. Ltd., Beijing, China,[5]China Novartis Institutes for Biomedical Research Co., Ltd., Shanghai, China,[6]Novartis Pharma AG, Basel, Switzerland,[7]Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
第一作者机构：[1]State Key Laboratory of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China,
推荐引用方式(GB/T 7714)：
Li J.,Kang J.,Wang C.,et al.Serum IgE Levels as Predictor for Treatment Outcomes in Chinese Patients with Moderate or Severe Allergic Asthma Treated with Omalizumab[J].AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.2018,197:
APA：
Li, J.,Kang, J.,Wang, C.,Yang, J.,Lin, Z....&Zhong, N..(2018).Serum IgE Levels as Predictor for Treatment Outcomes in Chinese Patients with Moderate or Severe Allergic Asthma Treated with Omalizumab.AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,197,
MLA：
Li, J.,et al."Serum IgE Levels as Predictor for Treatment Outcomes in Chinese Patients with Moderate or Severe Allergic Asthma Treated with Omalizumab".AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 197.(2018)
医学